+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Baculovirus Expression System - Global Strategic Business Report

  • PDF Icon

    Report

  • 373 Pages
  • May 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6089117
The global market for Baculovirus Expression System was valued at US$389.2 Million in 2024 and is projected to reach US$571.4 Million by 2030, growing at a CAGR of 6.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Baculovirus Expression System market.

Global Baculovirus Expression System Market - Key Trends & Drivers Summarized

Why Is the Baculovirus Expression System Emerging as a Versatile and Scalable Platform in Recombinant Protein Production, Vaccine Development, and Biomedical R&D?

The baculovirus expression system is gaining momentum as a preferred platform for high-yield, post-translationally competent production of complex recombinant proteins in eukaryotic systems. Leveraging insect cells - primarily Spodoptera frugiperda (Sf9, Sf21) or Trichoplusia ni (High Five) - this system supports proper protein folding, glycosylation, and assembly of multimeric structures that are difficult to replicate in prokaryotic hosts. Its compatibility with large gene inserts and capacity for high expression levels makes it ideal for structural biology, therapeutic protein manufacturing, and functional genomics applications.

Biopharmaceutical developers are increasingly using baculovirus vectors to produce vaccine antigens, viral-like particles (VLPs), and enzyme replacement therapies with human-like post-translational modifications. Notably, the system underpins the production of commercialized vaccines such as the FDA-approved Flublok influenza vaccine. The platform’s safety profile - owing to its non-replicative nature in mammalian cells - positions it as a low-risk, high-efficiency alternative for preclinical and clinical-grade protein production in regulated environments.

As the global life sciences sector prioritizes speed, yield, and fidelity in recombinant protein pipelines, the baculovirus system’s modularity, ease of scale-up in suspension cultures, and reduced endotoxin concerns are reinforcing its adoption. Academic, government, and commercial research labs are deploying it to address bottlenecks in protein structure-function studies, monoclonal antibody development, and assay reagent production, underscoring its role as a foundational bioprocessing tool across discovery and translational research domains.

How Are Vector Engineering, Host Cell Line Optimization, and Upstream Process Control Enhancing Platform Efficiency and Versatility?

Advances in vector engineering are significantly expanding the capabilities of the baculovirus expression system. Dual-promoter constructs, secretion signal enhancements, and multi-gene co-expression formats are enabling the simultaneous expression of complex protein assemblies, including membrane-bound proteins and virus-like particles. These developments are particularly impactful in vaccine design and structural biology, where native conformation and multi-subunit integrity are essential.

Host cell line optimization is also advancing, with genetically engineered insect cells now offering improved glycosylation fidelity, higher protein yields, and resistance to apoptosis during extended culture. High Five and Sf9 variants have been selectively adapted for serum-free, high-density suspension cultures, facilitating large-scale production in wave bioreactors and stirred-tank systems. These attributes support GMP-compliant manufacturing and accelerate transition from research to commercial-scale bioproduction.

Upstream process innovations - such as controlled infection timing, multiplicity of infection (MOI) modulation, and real-time metabolite profiling - are improving batch consistency and reducing variability in expression kinetics. Automated monitoring and feeding strategies, alongside high-throughput transfection screening, are being integrated into process development workflows. Collectively, these enhancements are reinforcing the system’s scalability, reproducibility, and adaptability across a range of recombinant protein targets.

Which Application Segments, End-User Markets, and Regulatory Trends Are Driving Commercial Adoption of Baculovirus Systems?

Vaccine development remains the most commercially visible application for baculovirus expression systems, particularly for influenza, HPV, and emerging infectious disease candidates. The platform’s ability to generate immunogenic VLPs and structural proteins with near-native folding has positioned it as a frontrunner in next-generation vaccine design. Public health preparedness programs and pandemic response strategies are increasingly incorporating baculovirus-produced antigens for rapid immunogen development and stockpiling.

Biopharmaceutical and contract development and manufacturing organizations (CDMOs) are expanding use of baculovirus systems for therapeutic protein production, especially in preclinical and early-phase clinical trials. The platform is being used to express recombinant enzymes, cytokines, and monoclonal antibodies where mammalian systems are cost-prohibitive or where rapid turnaround is required. Academic and government research institutions also form a robust end-user base, relying on baculovirus for laboratory-scale production of proteins for structural and functional analysis.

Regulatory acceptance of baculovirus-derived products is steadily increasing, supported by validated manufacturing protocols, low contamination risks, and favorable safety profiles. Agencies including the FDA, EMA, and WHO have cleared products derived from the system, reinforcing its credibility in biopharmaceutical pipelines. As global harmonization of biologics manufacturing advances, the baculovirus platform is expected to benefit from streamlined regulatory pathways, particularly in markets emphasizing flexible, scalable, and rapid-response biologics production models.

How Are CDMO Partnerships, Platform Standardization, and Digital Bioprocessing Enhancing Market Scalability and Adoption?

Strategic partnerships between innovators and CDMOs are accelerating industrial-scale deployment of baculovirus systems. CDMOs are investing in platform standardization, ready-to-use expression kits, and validated bioprocess templates to reduce tech transfer timelines and ensure lot-to-lot consistency. These collaborations are enabling biotech startups and mid-sized developers to access advanced manufacturing capabilities without incurring high capital expenditure.

Platform standardization is also reducing development time and simplifying regulatory compliance. Commercial expression systems - such as Bac-to-Bac®, flashBAC™, and BacMam - offer turnkey solutions with streamlined cloning, bacmid preparation, and transfection workflows. These platforms provide modular scalability from benchtop to pilot scale and support cGMP compliance through well-characterized documentation and process controls.

Digital bioprocessing is emerging as a differentiator in optimizing baculovirus-based production. Real-time analytics, PAT (Process Analytical Technology) frameworks, and AI-assisted parameter tuning are enabling precise control of infection kinetics, yield optimization, and quality assurance. These tools are enhancing predictability and reducing process development cycles, which is particularly valuable in time-sensitive contexts such as vaccine pandemics or personalized biologics manufacturing.

What Are the Factors Driving Growth in the Baculovirus Expression System Market?

The baculovirus expression system market is expanding as demand rises for rapid, high-fidelity protein production platforms that bridge the gap between research and commercial-scale biomanufacturing. The platform’s versatility, safety, and scalability are positioning it as a preferred solution for complex biologics development.

Key growth drivers include increasing vaccine development pipelines, demand for high-quality recombinant proteins, regulatory acceptance of baculovirus-derived products, and CDMO investment in insect-cell-based manufacturing capacity. Advancements in vector design, host cell engineering, and process automation are further accelerating adoption across R&D and therapeutic domains.

As global biologics markets prioritize modularity, speed, and structural accuracy, could the baculovirus expression system evolve into a mainstream platform not just for research-grade proteins, but for next-generation vaccines, therapeutic biologics, and real-time biomanufacturing under digitally managed production ecosystems?

Report Scope

The report analyzes the Baculovirus Expression System market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product Type (Baculovirus, Expression Vector, Reagents, Other Product Types); Application (Therapeutics, Vaccines, Protein Purification, Other Applications); End-User (Biopharmaceutical Companies, Research Institutes, Other End-Users).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Baculovirus segment, which is expected to reach US$251.5 Million by 2030 with a CAGR of a 5.3%. The Expression Vector segment is also set to grow at 8.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $106.0 Million in 2024, and China, forecasted to grow at an impressive 10.1% CAGR to reach $116.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Baculovirus Expression System Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Baculovirus Expression System Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Baculovirus Expression System Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Absolute Antibody, Agilent Technologies Inc., Aragen Bioscience Inc., Biointron Biological Inc., Bioneer Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Baculovirus Expression System market report include:

  • Absolute Antibody
  • Agilent Technologies Inc.
  • Aragen Bioscience Inc.
  • Biointron Biological Inc.
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Creative Biogene
  • Creative Biolabs
  • Cusabio Technology LLC
  • Evotec SE
  • Expression Systems, LLC
  • Fujifilm Diosynth Biotechnologies
  • GenScript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA
  • New England Biolabs
  • Oxford Expression Technologies Ltd.
  • Promega Corporation
  • Protein Sciences Corporation
  • Proteogenix

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Baculovirus Expression System - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Adoption in Recombinant Protein Production Throws the Spotlight on Baculovirus Expression Systems
  • Growth in Vaccine and Biologics Development Spurs Use of Insect Cell-Based Expression Platforms
  • Expansion of Viral Vector and Antigen Production Pipelines Bodes Well for Baculovirus-Based Production
  • Adoption in Gene Therapy and Diagnostic Reagent Manufacturing Broadens Application Scope
  • OEM Innovation in Bacmid Design and Co-Expression Vectors Accelerates Multi-Gene Constructs
  • Increased Demand for Cost-Effective and Animal-Free Expression Systems Supports Platform Growth
  • Use in High-Throughput Screening for Functional Genomics Enhances Discovery Research
  • Academic and CRO Adoption Expands Utility in R&D-Driven Protein Expression Projects
  • Global Vaccine Manufacturing Initiatives Incorporating Baculovirus Systems Accelerate Time to Market
  • Regulatory Acceptance of Baculovirus-Derived Biologics Strengthens Platform Credibility
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Baculovirus Expression System Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Baculovirus Expression System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Baculovirus Expression System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Baculovirus Expression System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Baculovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Baculovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Baculovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Expression Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Expression Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Expression Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 30: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 31: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Protein Purification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 33: World Historic Review for Protein Purification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 34: World 15-Year Perspective for Protein Purification by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • Table 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • Table 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Baculovirus Expression System Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Absolute Antibody
  • Agilent Technologies Inc.
  • Aragen Bioscience Inc.
  • Biointron Biological Inc.
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Creative Biogene
  • Creative Biolabs
  • Cusabio Technology LLC
  • Evotec SE
  • Expression Systems, LLC
  • Fujifilm Diosynth Biotechnologies
  • GenScript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA
  • New England Biolabs
  • Oxford Expression Technologies Ltd.
  • Promega Corporation
  • Protein Sciences Corporation
  • Proteogenix

Table Information